Jackie L Gartner-Schmidt1, Adrianna C Shembel2, Thomas G Zullo3, Clark A Rosen2. 1. Department of Otolaryngology, University of Pittsburgh Voice Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. Electronic address: jgs@pitt.edu. 2. Department of Otolaryngology, University of Pittsburgh Voice Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania. 3. Department of Dental Public Health, University of Pittsburgh Voice Center, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.
Abstract
OBJECTIVES: To (1) develop and validate the Dyspnea Index (DI); (2) quantify severity of symptoms in upper airway dyspnea; and (3) validate the DI as an outcome measure. STUDY DESIGN: Survey development and validation. METHODS: Three hundred sixty-nine participants were recruited for different phases of the study. Two hundred participants with chief complaints of dyspnea were given a 41-item questionnaire addressing common symptoms of dyspnea related to the upper airway. The questions were then reduced based on principal component analysis (PCA) and internal consistency resulting in a 10-item questionnaire. Cognitive interviews were conducted with 15 participants. Test-retest reliability and discriminant validity were measured from 51 participants. The DI was further validated by administering the index to 57 healthy controls (HC). Validation of the DI as a treatment outcome tool occurred with 46 participants' pre- and post-treatment scores. RESULTS: PCA revealed that only a single factor was being measured in both the original 41- and 10-item questionnaires. Additional cognitive interviewing suggested that no modification was needed to the DI. Test-retest reliability was r = 0.83. Discriminant validity was r = 0.62. The Mann-Whitney test demonstrated significant differences between healthy/symptomatic participants. Scores from the HC cohort resulted in a mean of 3.12 (SEM = 0.484; SD = 3.65) for the normative values. CONCLUSIONS: The DI is an effective and efficient instrument to quantify patients' symptoms of upper airway dyspnea. It is a statistically robust index, with significant reliability and validity, and can be dependably used as a treatment outcome measure.
OBJECTIVES: To (1) develop and validate the Dyspnea Index (DI); (2) quantify severity of symptoms in upper airway dyspnea; and (3) validate the DI as an outcome measure. STUDY DESIGN: Survey development and validation. METHODS: Three hundred sixty-nine participants were recruited for different phases of the study. Two hundred participants with chief complaints of dyspnea were given a 41-item questionnaire addressing common symptoms of dyspnea related to the upper airway. The questions were then reduced based on principal component analysis (PCA) and internal consistency resulting in a 10-item questionnaire. Cognitive interviews were conducted with 15 participants. Test-retest reliability and discriminant validity were measured from 51 participants. The DI was further validated by administering the index to 57 healthy controls (HC). Validation of the DI as a treatment outcome tool occurred with 46 participants' pre- and post-treatment scores. RESULTS: PCA revealed that only a single factor was being measured in both the original 41- and 10-item questionnaires. Additional cognitive interviewing suggested that no modification was needed to the DI. Test-retest reliability was r = 0.83. Discriminant validity was r = 0.62. The Mann-Whitney test demonstrated significant differences between healthy/symptomatic participants. Scores from the HC cohort resulted in a mean of 3.12 (SEM = 0.484; SD = 3.65) for the normative values. CONCLUSIONS: The DI is an effective and efficient instrument to quantify patients' symptoms of upper airway dyspnea. It is a statistically robust index, with significant reliability and validity, and can be dependably used as a treatment outcome measure.
Authors: Brianna K Crawley; Salem Dehom; Cedric Thiel; Jin Yang; Andrea Cragoe; Iman Mousselli; Priya Krishna; Thomas Murry Journal: JAMA Otolaryngol Head Neck Surg Date: 2018-07-01 Impact factor: 6.223
Authors: Meaghan Noud; Kristen Hovis; Alexander Gelbard; Nila A Sathe; David F Penson; Irene D Feurer; Melissa L McPheeters; David O Francis Journal: JAMA Otolaryngol Head Neck Surg Date: 2017-08-01 Impact factor: 6.223
Authors: Idris Samad; Lee Akst; Selmin Karatayli-Özgürsoy; Kristine Teets; Marissa Simpson; Ashwyn Sharma; Simon R A Best; Alexander T Hillel Journal: JAMA Otolaryngol Head Neck Surg Date: 2016-11-01 Impact factor: 6.223